Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Ventavia Research Group LLC

Neither a doctor nor a teaching hospital

Research payments

$50,959,791

4,596 payments

Through program year 2024, Ventavia Research Group LLC is reported as receiving $50,959,791 in research payments, across 4,596 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $470,156 79
2023 Research $3,885,913 404
2022 Research $13,979,440 1,665
2021 Research $17,734,636 1,482
2020 Research $12,093,469 596
2019 Research $2,796,177 370

Breakdown

Who paid Research payments · program years 2019–2024
  1. Pfizer Inc. $33,674,173 1,666 payments
  2. GlaxoSmithKline, LLC. $13,253,812 2,451 payments
  3. Bavarian Nordic A/S $2,847,927 146 payments
  4. Merck Sharp & Dohme Corporation $343,327 191 payments
  5. Janssen Research & Development, LLC $268,230 23 payments
  6. Allergan Inc. $224,042 58 payments
  7. H. Lundbeck A S $128,189 21 payments
  8. Novavax Inc $126,352 33 payments
  9. Moderna TX, Inc. $78,984 3 payments
  10. AstraZeneca Pharmaceuticals LP $10,038 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $12,731,253 260 payments
  2. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $11,422,867 528 payments
  3. Study name not reported $6,105,474 941 payments
  4. A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Countr $5,239,487 934 payments
  5. ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 $2,847,927 146 payments
  6. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $2,663,321 90 payments
  7. A Phase 2 Placebocontrolled Randomized Proof of Concept Study of A Respiratory Syncytial Virus RSV Vaccine in Pregnant Women $2,384,870 87 payments
  8. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $677,871 44 payments
  9. A Phase 23 Placebocontrolled Randomized Observerblind Study to Evaluate the Safety Tolerability and Immunogenicity of A Sarscov2 Rna Vaccine Candidate Bnt162b2 Against Covid19 in Healthy Pregnant Women 18 Years of Age and Older $677,498 117 payments
  10. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $669,273 45 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record